drugset / Trial / NCT03912441
First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, phase 1, "3+3 trial" of pharmacokinetics, safety and immunogenicity of BCD-147 (JSC "BIOCAD", Russia) after single administration of escalating doses in healthy male volunteers
Timeline
- Start
- 2019-01-30
- Primary completion
- 2019-09-30
- Completion
- 2019-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCD-147 | Monoclonal antibody | — | — |
Indications
No indication recorded.